DeepMed Research

Alliance for Clinical Trials in Oncology

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2011-01-01

Employees: 251

Market Cap: -

Website: https://www.allianceforclinicaltrialsinoncology.org

Clinical Trials

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

Phase 2

Active, not recruiting

Conditions: B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Vincristine
Drug: Dexamethasone
Biological: Inotuzumab Ozogamicin
Drug: Cytarabine
Drug: Methotrexate
Drug: Methylprednisolone
Biological: Rituximab
Drug: Prednisone
Drug: Mercaptopurine
Drug: Doxorubicin

First Posted Date: 2022-03-31

Last Posted Date: 2025-04-02

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 68

Registration Number: NCT05303792

Locations: 🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States

and more 69 locations

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase 2

Active, not recruiting

Conditions: Unresectable Pancreatic Neuroendocrine Carcinoma
Metastatic Pancreatic Neuroendocrine Tumor

Interventions: Drug: Capecitabine
Drug: Lutetium Lu 177 Dotatate
Other: Quality-of-Life Assessment
Drug: Temozolomide
Other: Questionnaire Administration

First Posted Date: 2022-02-21

Last Posted Date: 2025-04-02

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 31

Registration Number: NCT05247905

Locations: 🇺🇸
Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee, United States
🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

and more 168 locations

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

Phase 2

Active, not recruiting

Conditions: Castration-Sensitive Prostate Carcinoma
Metastatic Prostate Carcinoma
Stage IV Prostate Cancer AJCC V8
Stage IVA Prostate Cancer AJCC V8
Stage IVB Prostate Cancer AJCC V8

Interventions: Other: Pharmacotherapy Discontinuation
Other: Follow-Up
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

First Posted Date: 2022-02-16

Last Posted Date: 2025-01-15

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 79

Registration Number: NCT05241860

Locations: 🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
🇺🇸
Mercy Hospital Fort Smith, Ft. Smith, Arkansas, United States
🇺🇸
CARTI Cancer Center, Little Rock, Arkansas, United States

and more 323 locations

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program

Phase 3

Recruiting

Conditions: Cigarette Smoking-Related Carcinoma

Interventions: Other: Informational Intervention
Behavioral: Smoking Cessation Intervention
Other: Health Promotion and Education
Other: Questionnaire Administration

First Posted Date: 2021-08-17

Last Posted Date: 2025-05-18

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 600

Registration Number: NCT05008848

Locations: 🇺🇸
Saint Mary's Hospital, Centralia, Illinois, United States
🇺🇸
Kingman Regional Medical Center, Kingman, Arizona, United States
🇺🇸
Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States

and more 188 locations

Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy

Phase 3

Active, not recruiting

Conditions: Breast Carcinoma
Mastectomy Patient

Interventions: Other: Best Practice
Device: Wound Dressing Material
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2021-08-04

Last Posted Date: 2025-04-29

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 216

Registration Number: NCT04989504

Locations: 🇺🇸
Helen F Graham Cancer Center, Newark, Delaware, United States
🇺🇸
Saint Francis Cancer Center, Greenville, South Carolina, United States
🇺🇸
Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States

and more 46 locations

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Phase 3

Recruiting

Conditions: Anorexia
Hematopoietic and Lymphoid Cell Neoplasm
Advanced Malignant Solid Neoplasm

Interventions: Drug: Olanzapine
Drug: Megestrol Acetate
Other: Questionnaire Administration

First Posted Date: 2021-06-25

Last Posted Date: 2025-04-02

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 360

Registration Number: NCT04939090

Locations: 🇺🇸
Illinois CancerCare - Washington, Washington, Illinois, United States
🇺🇸
Rush-Copley Healthcare Center, Yorkville, Illinois, United States
🇺🇸
Northwest Cancer Center - Main Campus, Crown Point, Indiana, United States

and more 269 locations

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Phase 2

Recruiting

Conditions: Angioimmunoblastic T-cell Lymphoma
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Enteropathy-Associated T-Cell Lymphoma
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
Follicular T-Cell Lymphoma
Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Peripheral T-Cell Lymphoma, Not Otherwise Specified

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Etoposide
Drug: Duvelisib
Drug: Oral azacitidine

First Posted Date: 2021-03-17

Last Posted Date: 2025-04-02

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 170

Registration Number: NCT04803201

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States

and more 77 locations

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation

Phase 3

Active, not recruiting

Conditions: BRCA1 Mutation
Breast Cancer
Breast Diseases
Breast Neoplasms
Breast Carcinoma
Neoplasms

Interventions: Drug: Placebo
Drug: Denosumab
Other: Quality-of-Life Assessment

First Posted Date: 2021-01-15

Last Posted Date: 2025-04-02

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 300

Registration Number: NCT04711109

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States
🇺🇸
Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States

and more 44 locations

Trying to Find the Correct Length of Treatment with Immune Checkpoint Therapy

Phase 3

Active, not recruiting

Conditions: Locally Advanced Urothelial Carcinoma
Locally Advanced Urethral Urothelial Carcinoma
Locally Advanced Renal Pelvis Urothelial Carcinoma
Locally Advanced Ureter Urothelial Carcinoma
Metastatic Urethral Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Metastatic Renal Pelvis Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Locally Advanced Bladder Urothelial Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Nivolumab
Drug: Atezolizumab
Drug: Durvalumab
Drug: Avelumab

First Posted Date: 2020-11-20

Last Posted Date: 2025-01-15

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 3

Registration Number: NCT04637594

Locations: 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 374 locations

Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

Phase 2

Completed

Conditions: Prostate Carcinoma

Interventions: Drug: Placebo Administration
Drug: Oxybutynin Chloride
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2020-10-23

Last Posted Date: 2025-03-30

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 88

Registration Number: NCT04600336

Locations: 🇺🇸
Arizona Breast Cancer Specialists-Gilbert, Gilbert, Arizona, United States
🇺🇸
Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States
🇺🇸
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States

and more 100 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy